openPR Logo
Press release

Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceuticals

07-04-2024 10:54 PM CET | Health & Medicine

Press release from: ABNewswire

Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui

DelveInsight's, "Advanced Gastric Carcinoma Pipeline Insight, 2024," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Gastric Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Advanced Gastric Carcinoma Research. Learn more about our innovative pipeline today! @ Advanced Gastric Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Advanced Gastric Carcinoma Pipeline Report

* July 2024:- AstraZeneca- A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03).
* July 2024:- LaNova Medicines Zhejiang Co., Ltd.- A Phase III, Open-Label, Multi Center, Randomized Study of LM-302 Versus Treatment of Physician's Choice (TPC) in Patients With CLDN18.2-Positive, Locally Advanced or Metastatic Gastric(GC) and Gastroesophageal Junction(GEJ) Adenocarcinoma.
* DelveInsight's Advanced Gastric Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Gastric Carcinoma treatment.
* The leading Advanced Gastric Carcinoma Companies such as Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
* Promising Advanced Gastric Carcinoma Therapies such as MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.

Stay informed about the cutting-edge advancements in Advanced Gastric Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Gastric Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Gastric Carcinoma Emerging Drugs Profile

* Camrelizumab: Jiangsu Hengrui Medicine

Camrelizumab (formerly known as HR 301210, INCSHR 1210, SHR 1210) is a humanised high-affinity IgG4-kappa monoclonal antibody that targets the programmed cell death-1 receptor. Currently, it is in Phase III stage of clinical trial evaluation to treat advanced gastric or gastroesophageal junction adenocarcinoma.

* Pamiparib: BeiGene

Pamiparib (BGB-290) is an investigational small molecule inhibitor of PARP1 and PARP2. Pamiparib is being evaluated as a monotherapy in pivotal clinical trials in China in recurrent platinum-sensitive and BRCA1/2 mutated ovarian cancers. It is currently in global clinical development as a monotherapy, and in combination with other agents, including BeiGene's investigational anti-PD1 antibody, tislelizumab (BGB-A317), for a variety of solid tumor malignancies.

Learn more about Advanced Gastric Carcinoma Drugs Opportunities in our groundbreaking Advanced Gastric Carcinoma Research and development projects @ Advanced Gastric Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Advanced Gastric Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type

Advanced Gastric Carcinoma Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Discover the latest advancements in Advanced Gastric Carcinoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Gastric Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Advanced Gastric Carcinoma Pipeline Report

* Coverage- Global
* Advanced Gastric Carcinoma Companies- Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co.,Ltd., Bristol-Myers Squibb, Hanmi Pharmaceutical, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Idience Co., Ltd., Shanghai Henlius Biotech, AstraZeneca, Nanjing Legend Biotech Co., ALX Oncology Inc., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Genentech, Innovent Biologics (Suzhou) Co. Ltd., Qilu Pharmaceutical Co., Ltd., NextCure, Inc., Chengdu Kanghong Biotech Co., Ltd., GeneQuantum Healthcare (Suzhou) Co., Ltd., Janssen Pharmaceutical K.K., Shanghai Miracogen Inc., Ambrx, Inc., Imugene Limited, Vedanta Biosciences, Inc., Celon Pharma SA, Bicycle Tx Limited, Seagen Inc., and others.
* Advanced Gastric Carcinoma Therapies- MEDI4736, Bevacizumab, KN026, Zanidatamab, Tislelizumab, Trastuzumab, and others.
* Advanced Gastric Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Advanced Gastric Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Gastric Carcinoma Pipeline on our website @ Advanced Gastric Carcinoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/advanced-gastric-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Advanced Gastric Carcinoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Advanced Gastric Carcinoma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Camrelizumab: Jiangsu Hengrui Medicine
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Pamiparib: BeiGene
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Venadaparib: Idience
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Advanced Gastric Carcinoma Key Companies
* Advanced Gastric Carcinoma Key Products
* Advanced Gastric Carcinoma- Unmet Needs
* Advanced Gastric Carcinoma- Market Drivers and Barriers
* Advanced Gastric Carcinoma- Future Perspectives and Conclusion
* Advanced Gastric Carcinoma Analyst Views
* Advanced Gastric Carcinoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=advanced-gastric-carcinoma-pipeline-2024-jiangsu-hengrui-medicine-beigene-cspc-zhongqi-pharmaceutical-technology-lintonpharm-co-ltd-bristolmyers-squibb-hanmi-pharmaceuticals]
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Advanced Gastric Carcinoma Pipeline 2024 | Jiangsu Hengrui Medicine, BeiGene, CSPC ZhongQi Pharmaceutical Technology, LintonPharm Co., Ltd., Bristol-Myers Squibb, Hanmi Pharmaceuticals here

News-ID: 3566995 • Views:

More Releases from ABNewswire

Aspen Artist Shelly Hamill Celebrates 25 Years of Transforming Heirloom China Into Contemporary Mosaic Art
Aspen Artist Shelly Hamill Celebrates 25 Years of Transforming Heirloom China In …
Renowned mosaic artist Shelly Hamill marks over 25 years of creating unique sculptures from recycled china, offering collectors a meaningful way to transform family heirlooms into displayable art. Trained as a Master of Mosaic in portraiture at the prestigious Orsoni studio in Venice, Italy, Hamill now expands her offerings with a new print-on-demand service and an innovative Print of the Month Club. Shelly Hamill has spent more than a quarter century
Earned Everyday: Military Veterans Launch Athletic Brand Teaching Youth That Confidence Comes From Hard Work
Earned Everyday: Military Veterans Launch Athletic Brand Teaching Youth That Con …
Husband-and-wife Veteran team Matthew and Crystal Rorebeck have transformed their military experience and parenting journey into Earned Everyday, a Weatherford/Aledo athletic apparel brand with a powerful message for young athletes. Drawing from 46 combined years of military service and raising six children through deployment cycles, the retired Majors created a brand that teaches resilience, dedication, and the value of earning success. A new athletic apparel brand with deep roots in military
Pick-A-Part Jalopy Jungle Offers Top Dollar Cash for Unwanted Vehicles Across Southern Idaho
Pick-A-Part Jalopy Jungle Offers Top Dollar Cash for Unwanted Vehicles Across So …
Pick-A-Part Jalopy Jungle announces expanded cash-for-cars services across five locations in the Treasure and Magic Valleys, including Boise, Garden City, Nampa, Caldwell, and Twin Falls. The company provides free towing and guarantees competitive prices for unwanted vehicles while offering budget-friendly used auto parts for DIY mechanics. Vehicle owners throughout the Treasure and Magic Valleys now have a convenient solution for selling unwanted cars, trucks, and other vehicles thanks to Pick-A-Part Jalopy
Health & Hygiene Packaging Market Segmentation, Top Players, Industry Growth Drivers and Strategic Developments 2025-2028
Health & Hygiene Packaging Market Segmentation, Top Players, Industry Growth Dri …
The Health & Hygiene Packaging Market is growing steadily, driven by rising consumer awareness, stricter safety standards, and demand for secure, contamination-free products. Key players such as Amcor, Mondi, Berry Global, BASF, and Huhtamaki are focusing on sustainable materials, advanced barrier technologies, and innovative designs to enhance product protection, portability, and hygiene across end-use sectors. The global Health and hygiene Packaging market size is estimated to be USD 110.9 billion in

All 5 Releases


More Releases for Gastric

Rising Gastric Cancer Cases Fuel Growth In Gastric Cancer Drugs Market Driving M …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Gastric Cancer Drugs Market Size By 2025? In recent times, the market size for gastric cancer drugs has seen a swift expansion. Projections forecast growth from $4.41 billion in 2024 to $4.9 billion in 2025, a compound annual growth rate (CAGR) of 11.2%. Factors contributing
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driving Marke …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Gastric Ulcers Market Size By 2025? In the last few years, the market size for gastric ulcers has been expanding notably. It is anticipated to increase from $4.29 billion in 2024 to $4.54 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.9%.
Increasing Geriatric Population Fuels Gastric Ulcers Market Growth Driver: Leadi …
How Are the key drivers contributing to the expansion of the gastric ulcers market? The rising geriatric population is expected to accelerate the growth of the gastric ulcers market. The geriatric population, typically individuals aged 65 and above, is growing due to improvements in healthcare and increased life expectancy. This population is more susceptible to gastric ulcers due to factors like the use of NSAIDs and decreased mucosal protection. For instance,
Top Factor Driving Gastric Cancer Drugs Market Growth in 2025: Rising Gastric Ca …
What market dynamics are playing a key role in accelerating the growth of the gastric cancer drugs market? The rise in obesity and smoking rates has led to an increased prevalence of gastric cancer. Factors like tobacco use and poor dietary habits have been linked to a higher risk of developing this disease. As per data from the Government Digital Service in the UK, it was projected in May 2023 that
Gastric Cancer Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Gastric Cancer
Gastric Function Test Market - Empowering Digestive Health: Gastric Function Tes …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Gastric Function Test Market. Gastric Function Test Market: https://www.growthplusreports.com/report/gastric-function-test-market/9126 The Gastric Function Test Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the